Table 2.
Combined Effect of LN Involvement and Microscopic Residual Disease
| Status (microscopic residual disease/LNs) | No. of Patients | 8-Year EFS (%) | P | 8-Year OS (%) | P |
|---|---|---|---|---|---|
| Stage III (with and without distant metastatic disease) | .008 | .07 | |||
| Negative/negative | 52 | 90 | 95 | ||
| Negative/positive | 244 | 83 | 91 | ||
| Positive/negative | 170 | 84 | 94 | ||
| Positive/positive | 103 | 71 | 86 | ||
| Stage III (no distant metastatic disease) | .004 | .14 | |||
| Negative/negative | 49 | 91 | 94 | ||
| Negative/positive | 187 | 84 | 92 | ||
| Positive/negative | 156 | 86 | 96 | ||
| Positive/positive | 68 | 69 | 89 |
Abbreviations: EFS, event-free survival; LN, lymph node; OS, overall survival.